Filing Flows › Tela Bio (TELA) › Q3 2025
Tela Bio (TELA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
Tela Bio (TELA) reported revenue of $20.7M for the third quarter 2025 (Q3 2025), +9% from a year earlier and +2% from the quarter before. Operating margin was -36.5%, net loss $8.6M (41.6% of revenue).
Tela Bio, Q3 2025: revenue $20.7M (+9% year over year), operating margin -36.5%, net loss $8.6M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.7M | +2% | +9% |
| Operating profit | −$7.6M | — | — |
| Net earnings | −$8.6M | — | — |
| Operating cash flow | −$5.7M | — | — |
What changed
Revenue was $20.7M in Q3 2025, up 9% year over year and up 2% from the previous quarter.
Gross margin was 67.5%, down 0.3 points from a year earlier. Operating costs exceeded revenue by $7.6M, an operating margin of -36.5%. Operating expenses fell 3% while revenue rose 9%. The fastest-growing cost line was Research & development (+14%). The quarter ended with a net loss of $8.6M, narrower than the previous quarter's $9.9M loss.
Operating cash flow was −$5.7M. Non-cash charges added back $153K of depreciation and $1.0M of share-based compensation. Working capital and other items added $1.8M. Capital expenditures of $211K exceeded it, leaving free cash flow of −$5.9M.
Questions
What was Tela Bio's revenue in the third quarter 2025?
Tela Bio (TELA) reported revenue of $20.7M for the third quarter 2025 (Q3 2025), +9% from a year earlier and +2% from the quarter before.
Was Tela Bio profitable in the third quarter 2025?
Operating loss was $7.6M (-36.5% of revenue) and net loss $8.6M.
Source: Tela Bio 10-Q on SEC EDGAR.